GUTS 6-month open-label data released this morning and continues to validate Revita as a procedure that can solidify the weight loss and health benefits of GLP-1s (while allowing for cold turkey GLP-1 discontinuation). Was slightly worried we could see some more significant weight regain, but this is nice to see. Just another incremental validator of Revita. The next few quarters will continue to expand the data set, with key placebo-controlled 6-month data due in January, then the 1-year data sets, and then the 300+ patients pivotal cohort in the “very early” part of 2H26. The sell-off is not surprising given how this has traded recently—people are largely unaware of the story. Setting up for a great 2026.